GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Deferred Policy Acquisition Costs

Sunesis Pharmaceuticals (FRA:RYIS) Deferred Policy Acquisition Costs


View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.